Sarepta Therapeutics, Inc. (SRPT)
22.50
-0.49
(-2.13%)
USD |
NASDAQ |
Sep 04, 16:00
22.50
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Research and Development Expense (Quarterly) : 91.26M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 91.26M |
| March 31, 2026 | 153.96M |
| December 31, 2025 | 319.50M |
| September 30, 2025 | 218.89M |
| June 30, 2025 | 204.39M |
| March 31, 2025 | 773.45M |
| December 31, 2024 | 192.60M |
| September 30, 2024 | 217.82M |
| June 30, 2024 | 173.71M |
| March 31, 2024 | 194.35M |
| December 31, 2023 | 187.30M |
| September 30, 2023 | 186.19M |
| June 30, 2023 | 233.76M |
| March 31, 2023 | 237.13M |
| December 31, 2022 | 205.79M |
| September 30, 2022 | 208.54M |
| June 30, 2022 | 244.82M |
| March 31, 2022 | 186.23M |
| December 31, 2021 | 190.05M |
| September 30, 2021 | 131.67M |
| June 30, 2021 | 233.56M |
| March 31, 2021 | 188.61M |
| December 31, 2020 | 201.98M |
| September 30, 2020 | 185.92M |
| June 30, 2020 | 184.32M |
| Date | Value |
|---|---|
| March 31, 2020 | 131.97M |
| December 31, 2019 | 222.94M |
| September 30, 2019 | 133.95M |
| June 30, 2019 | 113.27M |
| March 31, 2019 | 90.55M |
| December 31, 2018 | 142.41M |
| September 30, 2018 | 86.58M |
| June 30, 2018 | 122.85M |
| March 31, 2018 | 46.20M |
| December 31, 2017 | 44.44M |
| September 30, 2017 | 34.23M |
| June 30, 2017 | 58.91M |
| March 31, 2017 | 29.05M |
| December 31, 2016 | 70.75M |
| September 30, 2016 | 33.58M |
| June 30, 2016 | 43.84M |
| March 31, 2016 | 38.32M |
| December 31, 2015 | 41.38M |
| September 30, 2015 | 36.67M |
| June 30, 2015 | 29.18M |
| March 31, 2015 | 39.16M |
| December 31, 2014 | 30.83M |
| September 30, 2014 | 21.85M |
| June 30, 2014 | 20.64M |
| March 31, 2014 | 20.91M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 588.00M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Beam Therapeutics, Inc. | 95.10M |
| Twist Bioscience Corp. | 18.02M |
| ImmunityBio, Inc. | 60.82M |